The North America Pharmacogenomics Market is expected to reach US$ 6,534.83 million by 2028 from US$ 3,333.43 million in 2021. it is estimated to grow at a CAGR of 10.1% from 2021 to 2028.
The key factors driving the growth of this market are the increasing prevalence of chronic diseases, the surge in demand for precision medicines, and the rise in funding for pharmacogenomic research activities. However, the shortage of skilled professionals is expected to restrict the market growth during the forecast period.
NORTH AMERICA PHARMACOGENOMICS MARKET SEGMENTATION
North America Pharmacogenomics Market By Technology
-
Hospitals & Clinics
-
Biopharmaceutical Companies
-
CROs and CDMOs
-
Others
North America Pharmacogenomics Market By Application
-
PCR
-
Sequencing
-
Microarray
-
gel electrophoresis
-
mass spectrometry
-
Others
North America Pharmacogenomics Market By End User
-
Drugs Discovery
-
Oncology
-
Neurological & Psychiatry
-
Pain Management
-
Cardiovascular
-
Others
North America Pharmacogenomics Market By Country
-
US
-
Canada
-
Mexico
North America Pharmacogenomics Market Company Profiles
-
Abbott
-
F. HOFFMANN-LA ROCHE LTD.
-
Oxford Nanopore Technologies
-
THERMO FISHER SCIENTIFIC INC.
-
Illumina, Inc.
-
QIAGEN
-
Agilent Technologies, Inc.
-
Myriad Genetics, Inc.
-
Admera Healt
The Growing Burden of Chronic Diseases and the Role of Pharmacogenomics
Chronic diseases are a significant global health challenge, particularly among older adults. Over 60% of individuals aged 60 and above suffer from two or more chronic conditions. Twin studies have demonstrated that genetic factors play a critical role in the development of chronic diseases such as cardiovascular diseases (CVDs), diabetes, obesity, rheumatoid arthritis (RA), Alzheimer’s disease (AD), and depression. Advances in molecular genetics, particularly through genome-wide association studies (GWAS), now enable the measurement of individual-level genetic risks for these conditions. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 60% of Americans had at least one chronic disease, while 40% had two or more.
The Impact of Chronic Diseases
Cardiovascular diseases, including atherosclerosis, angina pectoris, and acute myocardial infarction, are among the leading causes of death worldwide. Driven by hectic lifestyles, CVDs account for approximately 17.9 million deaths annually, as reported by the World Health Organization (WHO). Diabetes, another life-threatening condition with no cure, poses severe risks such as heart attacks, strokes, kidney failure, limb amputations, vision loss, and nerve damage. The International Diabetes Federation (IDF) estimates that in 2017, 46 million people in North America had diabetes, a number projected to rise to 62 million by 2045. Globally, diabetes cases are expected to increase from 425 million in 2017 to 629 million by 2045, representing a 35% rise.
Alzheimer’s disease is another growing concern, with 55 million cases reported worldwide in 2020, according to the Alzheimer’s Association. The rapid rise in chronic diseases has accelerated research into genomics and its potential to treat life-threatening illnesses, fueling market growth over the past five years.
The Rise of Pharmacogenomics
Pharmacogenomics, the study of how genes affect an individual’s response to drugs, is increasingly being integrated into clinical practice. Government investments exceeding $4 billion across at least 14 countries are supporting the implementation of genomic medicine in healthcare systems. These national initiatives aim to drive transformative changes, address implementation barriers, and gather evidence for broader adoption.
In August 2018, Boston Scientific Corporation, a Massachusetts-based company, secured $4.3 million in seed funding and partnered with Veritas Genetics to advance personal genome sequencing. This initiative aims to create a secure, decentralized marketplace for genomic data, reflecting the growing commitment of manufacturers and governments to genomics research. Such investments are propelling the pharmacogenomics market forward.
Strategic Insights for the North America Pharmacogenomics Market
Strategic insights into the North America pharmacogenomics market provide a data-driven analysis of the industry landscape, highlighting current trends, key players, and regional dynamics. These insights offer actionable recommendations, enabling stakeholders to identify untapped opportunities and develop unique value propositions. By leveraging data analytics, industry players—whether investors, manufacturers, or other stakeholders—can anticipate market shifts and position themselves for long-term success. A forward-looking perspective is essential in this rapidly evolving field, helping stakeholders make informed decisions that drive profitability and achieve their business objectives. Ultimately, these insights empower stakeholders to navigate the complexities of the pharmacogenomics market and capitalize on emerging opportunities in North America.
Other Reports:
North America Cosmetic Packaging Market: https://business-news-insights.blogspot.com/2025/03/north-america-cosmetic-packaging-market.html
North America Augmented Reality and Virtual Reality Market: https://sites.google.com/view/ar-and-vr-market1/home
North America 3D Animation Software Market: https://www.quora.com/profile/Business-Market-Insights-1/North-America-3D-Animation-Software-Market-Business-Strategy-Development-Status-Emerging-Technologies-2028-The-North
Europe Baby Infant Formula Market: https://www.reddit.com/r/combinationfeeding/comments/1jaccm5/europe_baby_infant_formula_market_key_details_and/
Europe Neuromodulation Market: https://penzu.com/p/ccf4c4d5db4dd31d
Europe Frozen Fruits Market: https://postyourarticle.com/wp-admineurope-frozen-fruits-market-trends-size-developments-status-and-key-players-analysis-2027/
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
